INBRAIN Neuroelectronics Closes $50M Series B to Accelerate Graphene-Based Brain-Computer Interface Technology

In a world where big, next- gen innovation in almost any industry seems to come from industry titans, this week brings us a success story from a startup working on changing how we communicate with the world.

Carolina Aguilar, CEO and co-founder of Spanish pioneering brain-computer interface therapeutics (BCI-Tx) startup INBRAIN Neuroelectronics, announced the closing of a $50 million Series B funding round. The round was led by Belgian nano-electronics manufacturer associated fund imec.xpand with new participation from EIC Fund, Fond ICO Next Tech, CDTI-Innvierte, and Avançsa. Existing investors Asabys Partners, Aliath Bioventures, and Vsquared also joined, bringing INBRAIN’s total funding since inception to $68 million. MedTech World extends warm congratulations to INBRAIN Neuroelectronics on this significant achievement.

Celebrating the milestone, Carolina says, “Behind every meaningful CEO there is a better team, I’m incredibly proud of INBRAIN’s achievement in pioneering the world’s first application of graphene in humans—a milestone that redefines what’s possible in neurotechnology. This breakthrough, alongside our successful Series B round, is a powerful endorsement of our mission to create safer, smarter, and more personalized solutions in neural health. We’re committed to pushing boundaries to improve lives and revolutionize the way we treat neurological disorders through BCI therapeutics.”

This funding will accelerate INBRAIN’s development of its graphene-based BCI-Tx platform, which enables ultra-precise decoding and modulation of neural signals. The company’s breakthrough neural interface technology includes an implant only 10 micrometers thick—thinner than a human hair—that leverages graphene’s unique properties of strength, flexibility, and conductivity for exceptional performance in real-time precision neurology, supported by artificial intelligence neural networks.

Besides the Series B funding, INBRAIN secured additional backing from long-time partner Merck KGaA to expand the clinical applications of its neural interface technology across Merck’s therapeutic areas of interest. This collaboration is set to propel INBRAIN’s platform toward human applications for both central and peripheral nervous system disorders.

As part of this financing, INBRAIN has announced a strategic collaboration with imec, a global leader in nanoelectronics, to support commercial scaling of graphene interfaces. INBRAIN also achieved a groundbreaking milestone with the world’s first human trial of its graphene-based BCI-Tx at Salford Royal Hospital in Manchester, UK. The trial aims to establish the safety and potential advantages of graphene for neural technologies in patients with brain cancer, with up to ten participants slated to evaluate this promising technology.

This first-in-human trial propels INBRAIN into the rarified sphere of the few clinical-stage implanted human brain interface companies, along with Neuralink (of Elon Musk), Synchron (backed by Jeff Bezos and Bill Gates), Precision Neuroscience (formed by former Neuralink employees), Blackrock Neurotech, and the BrainGate research collaborative. Another notable company racing towards clinical trials in this space is Paradromics.

INBRAIN CEO is a frequent conference speaker and staunch ally to other medtech and hardtech founders.

The MedTech World team enjoyed her insightful comments on the panel ‘How we do it: Investors and Entrepreneurs together’ at MedTech Malta last year and salutes her for this success.

MedTech Malta 2024: Only Two Days to Go!

The countdown to MedTech Malta 2024 has begun! This landmark event, running from November 6-8 in Valletta, will unite groundbreaking startups, leading investors, and key MedTech professionals. Join us to connect with visionaries in healthcare innovation. Don’t miss out—secure your tickets today for an unmatched industry experience!